LTHOUGH cerebral vasospasm following SAH has been recognized for longer than a half century, it remains a major complication in patients suffering from SAH. 9, 11, 12, 44 As there continues to be no consistently effective treatment for cerebral vasospasm, the pathophysiological mechanisms contributing to arterial dysfunction require further investigation. Basic molecular and cellular research implicates two major hypotheses as key to cerebral vasospasm. One hypothesis centers on the roles of nitric oxide and nitric oxide synthase, 21, 25, 35, 40, 41 and the other focuses on the role of inflammation.
not been clearly defined until recently. A growing body of evidence suggests that various constituents of the inflammatory response, including adhesion molecules, cytokines, leukocytes, immunoglobulins, and complement, may be critical in the pathogenesis of cerebral vasospasm. Adhesion molecules have been implicated in the pathogenesis of various diseases, including cerebral ischemia. 17 The relationship between adhesion molecules and delayed cerebral vasospasm following SAH has also been investigated. Among the adhesion molecules, the immunoglobulin-like superfamily (ICAM-1, -2, and -3, VCAM-1, and PECAMs) and the selectin family have all been studied in the context of SAH-induced vasospasm in both animal and human studies. [1] [2] [3] 7, 8, 18, 19, 22, 24, 32, [36] [37] [38] [39] 42, 45, 46, [48] [49] [50] Endothelin-1 is a potent vasoconstrictor that has been implicated in the pathogenesis of angiographic vasospasm. 31 It is initially produced as a large prepropeptide composed of approximately 212 amino acids. 23 Multiple steps of posttranslational processing are required to produce an active 21-amino acid polypeptide with nanomolar affinity for specific membrane receptors. The final conversion step in this process involves the proteolytic cleavage of a relatively inactive precursor, big ET-1 (~ 40 amino acids in length), to form ET-1. This cleavage is mediated by ECE, a phosphoramidon-sensitive metalloproteinase. 33 Extracellular ET-1 can alter cerebrovascular tone via interactions with specific ET receptors on the membranes of smooth muscle and endothelial cells.
14 As a result of the key role played by ECE in the production of active ET-1, it is plausible that ECE inhibitors could be of benefit in the treatment of diseases in which ET-1 overproduction or overactivity plays a pathogenic role. We previously investigated the effects of the ECE inhibitor, (S)-2 biphenyl-4yl-1-(1H-tetrazol-5-yl)-ethyl-amino-methyl phosphonic acid (CGS 26303), 26 on SAHinduced cerebral vasospasm. Intravenous bolus injections of CGS 26303 (30 mg/kg) administered twice daily either before or after the establishment of arterial narrowing were effective in the management of cerebral vasospasm pursuant to SAH. 26 Findings of several studies point to a role for ET-1 in the enhancement of adhesion molecule expression and leukocyte adhesion. Both ICAM-1 and VCAM-1 are constitutively expressed on cerebral microvascular endothelial cell lines derived from the human brain, and the expression of these molecules can be upregulated by ET-1, ET-2, and ET-3 in a dose-and time-dependent manner. 34 Data also indicate that ET-1 treatment induces the expression of E-selectin on these cells. 34 Culturing human coronary artery endothelial cells alone with ET-1 for 4 to 6 hours resulted in increased expression of the endothelial adhesion molecules E-selectin and ICAM-1, and significantly increased the number of adhering neutrophils. 15, 51 Endothelin-1 stimulates arterial VCAM-1 expression by producing superoxide (O 2Ϫ ) from an ET A receptor/reduced form of nicotinamide-adenine dinucleotide phosphate oxidase pathway in low-renin mineralocorticoid hypertension. 29 In deoxycorticosterone-salt rats, ET-1 participates in altered leukocyte-endothelial cell interactions via activation of the ET A receptors and possibly by modulating the expression of cell adhesion molecules (increased cardiac platelet selectin [P-selectin], which is detected mainly in endothelial cells, and VCAM-1 but not ICAM-1); the inflammatory status is associated with cardiac damage. 4 Taking these findings together, we designed this study to evaluate the relationship between SAH-induced vasospasm and plasma levels of ICAM-1, VCAM-1, and E-selectin. The effects of ECE inhibition on the prevention of cerebral vasospasm after SAH and on alterations in plasma levels of ICAM-1, VCAM-1, and E-selectin were also examined.
Materials and Methods

Induction of Experimental SAH
Thirty-six male New Zealand White rabbits, each weighing between 3.2 and 3.9 kg, were used in this study. All experimental protocols were approved by the University of Kaohsiung Medicine Animal Research Committee. The rabbits were anesthetized by an intramuscular injection of a mixture of 9 mg/kg xylazine and 55 mg/ kg KetaVed, and endotracheal intubation was initiated. Three milliliters of arterial blood was withdrawn from the central ear artery and injected into the cisterna magna using a 23-gauge butterfly needle. After the injection, the rabbits were placed in ventral recumbency, where they remained for 15 minutes to allow ventral blood clot formation. The animals were then monitored closely for respiratory distress and given mechanical ventilation as needed. Afterward, the endotracheal tube was removed and the animals were returned to the vivarium when fully awake.
General Design of Experiments and Treatment Groups
The rabbits were evenly divided into the following four groups (nine animals/group): 1) control (no SAH); 2) SAH only; 3) SAH plus vehicle; and 4) SAH plus CGS 26303 (30 mg/kg). The first injections given to animals were administered 1 hour after induction of SAH; subsequent injections were administered 12, 24, and 36 hours post-SAH, and the animals were killed by perfusion-fixation 48 hours after SAH.
Perfusion-Fixation
Forty-eight hours after they were subjected to SAH, the rabbits were again anesthetized, given endotracheal intubation and mechanical ventilation, and paralyzed by administration of pancuronium bromide (0.3 mg/kg). The central ear artery was cannulated to monitor blood pressure and to obtain blood samples to determine the levels of ICAM-1, VCAM-1, and E-selectin-l. Perfusion-fixation was subsequently performed. The thorax was opened, a cannula was placed in the left ventricle, the descending thoracic aorta was clamped, and the right atrium was opened. Perfusion was begun with 300 ml of Hanks balanced salt solution (pH 7.4), followed by 200 ml of a mixture of 2% paraformaldehyde and 2.5% glutaraldehyde in the same salt solution at 37˚C under a perfusion pressure of 120 cm H 2 O. Following perfusion-fixation, the brain was removed and immersed in the same fixative overnight at 4˚C. Visual inspection during removal of the brain showed that, in all animals whose cisterna magna received injections of blood, subarachnoid clots had formed and covered the BA.
Tissue Embedding
Basilar arteries were removed from the brainstems and the middle third of each artery was dissected for analysis. The arterial segments were washed several times with 0.1 mol/L PBS (pH 7.4), fixed in 1% osmium tetroxide in PBS for 1 hour at room temperature and then washed again with PBS. The vessel segments were dehydrated and placed in a 1:1 mixture of propylene oxide and epoxy resin overnight. The vessel segments were flat embedded the next day in 100% epoxy resin and allowed to polymerize at 60˚C for 48 hours. Crosssections (0.5 m in thickness) of the BAs were cut on a Ultracut E ultramicrotome (Reichert), mounted on glass slides, and stained with 0.5% toluidine blue for morphometric analysis.
Tissue Morphometric Studies and Statistical Analysis
Five randomly selected cross-sections from the BA of each animal were analyzed by an investigator blinded to the treatment groups. Automated measurements of the luminal cross-sectional area were made using computer-assisted morphometry (Image 1, Universal Imaging Corp.). Areas of five cross-sections from a given animal were averaged to provide a single value for each animal. Group data are expressed as the means Ϯ standard error of the means. For group comparisons, we performed an analysis of variance with the Bonferroni post-hoc test. Differences were considered significant at a probability value less than 0.05.
Assays for ICAM-1, VCAM-1, and E-selectin
We assayed the serum concentrations of ICAM-1, VCAM-1, and E-selectin by using commercially available enzyme-linked immunosorbent assay kits (R&D Systems) in accordance with the supplier's instructions. The assays involved the simultaneous reaction of sICAM, sVCAM, and sE-selectin (in sample or standard) to a monoclonal antibody precoated on the walls of microtiter plate wells and to an unbound second antibody directed against a different molecular epitope. The second antibody was conjugated to HRP. After removal of unreacted reagents, bound sICAM-HRP, sVCAM-HRP, and sE-selectin-HRP antibodies were detected by a reaction with an HRP-specific substrate (tetramethylbenzidine), which yielded a colored product proportional to the concentrations of sICAM, sVCAM, and sE-selectin (determined relative to an appropriate standard curve). Absorption measurements were obtained at 450 nm using a microtiter plate reader.
Results
General Observations
Prior to perfusion-fixation, there were no significant differences among the treatment groups in the physiological parameters recorded, including body weight, pH, PaCO 2 , PaO 2 , and mean arterial blood pressure. A thick subarachnoid clot was observed over the basal surface of the brainstem in each animal subjected to SAH. Morphologically, the BAs in the SAH only and SAH plus vehicle groups exhibited substantial corrugation of the IEL. Corrugation of the IEL was less prominent in animals treated with CGS 26303. Vessels from healthy control animals and CGS 26303-treated animals had similar IELs.
Cross-Sectional Areas of BAs
The cross-sectional areas of BAs were significantly reduced in animals subjected to SAH (Fig. 1) . The mean cross-sectional areas of BAs in the SAH only and SAH plus vehicle groups were reduced by 72 and 65%, respectively, when compared with the control (no SAH) group. Significant cerebral vasospasm did not develop in rabbits treated with CGS 26303 and the mean cross-sectional area in those animals was similar to that in controls (p = 0.237; Fig. 1 ). The protective effect of CGS 26303 achieved statistical significance when a comparison was made with the SAH only or SAH plus vehicle group (p Ͻ 0.001).
Levels of VCAM-1, ICAM-1, and E-selectin
Although there were trends for upregulation of VCAM-1 levels following induction of SAH, there were no statistically significant differences among the four groups (Fig. 2) . Levels of E-selectin were increased significantly in all animals subjected to SAH (SAH only, SAH plus vehicle treatment, and SAH plus CGS 26303 treatment group) when compared to levels of E-selectin in healthy controls (p Ͻ 0.01, p Ͻ 0.005, and p Ͻ 0.005, respectively; Fig. 3 ). Treatment with CGS 26303 had no effect on the increased levels of E-selectin after SAH. Levels of ICAM-1 in the SAH only and SAH plus vehicle groups were elevated when compared with the levels of ICAM-1 in the control group and significantly elevated when compared with the CGS 26303-treated group (p Ͻ 0.001; Fig. 4 ). Treatment with CGS 26303 reduced ICAM-1 to a mean level not significantly different from that of the control group (p = 0.299).
Discussion
Adhesion molecules have been implicated in the pathogenesis of various diseases, including cerebral ischemia; 17 however, the relationship between adhesion molecules and delayed cerebral vasospasm after SAH has been incompletely investigated. Among the adhesion molecules, members of the immunoglobulin-like superfamily (ICAM-1, -2, -3, VCAM-1, and PECAM), which are expressed by activated endothelium and act via binding to a leukocyte transmembrane protein, have been investigated for their roles in SAH-induced vasospasm in both animal and human studies. Handa et al. 20 demonstrated that ICAM-1 was expressed not only in the endothelial layer but also in the medial layer of the BA, with a correlation between the severity and timing of vasospasm in experimental SAH in rats. In a rat femoral artery model of vasospasm, upregulation of ICAM-1 was an early response, 45 and intraperitoneal administration of anti-ICAM monoclonal antibody significantly decreased the degree of vasospasm and the number of infiltrating leukocytes. 39 Bavbek et al. 2 showed that an intracisternal injection of anti-ICAM-1 and/or anti-CD18 attenuated vasospasm in a rabbit SAH model. Furthermore, administration of a monoclonal antibody against CD11 and CD18, the integrins that interact with ICAM-1, prevented vasospasm in a primate model of vasospasm. 6 After aneurysmal SAH, serum ICAM-1 levels increased, and patients with a poor outcome had significantly higher ICAM-1 levels when compared with patients who eventually attained a good outcome. 32 In a canine SAH model, increased expression of ICAM-1 was found to be maximal on Day 7 post-SAH, simultaneously with maximal narrowing of the BA lumen. 1 Ibuprofen, an antiinflammatory agent, has been shown to inhibit leukocyte-endothelial adhesion by suppression of interleukin-1␣ and tumor necrosis factor-␣-induced expression of ICAM-1 and VCAM-1. Moreover, ibuprofen attenuated vasospasm and decreased endothelial transmigration of leukocytes in a rat femoral artery vasospasm model. 48 Recent work by Tamargo's group 16, 43 has demonstrated local delivery of ibuprofen to be effective in the prevention of vasospasm in rabbit and primate models of vasospasm. Taken collectively, adhesion molecules involved in inflammation following SAH are implicated in the pathogenesis of cerebral vasospasm.
In this study, VCAM-1 levels did not differ significantly among groups. However, ICAM-1 levels in the CGS 26303 treatment group were significantly lower than those in the SAH only and SAH plus vehicle groups, and did not differ significantly from ICAM-1 levels in the control group. This finding implies that ECE inhibition may attenuate SAH-induced vasospasm by decreasing ICAM-1 production.
The selectin family of glycoprotein adhesion molecules (P-selectin, L-selectin, and E-selectin) has been implicated in the pathogenesis of a number of inflammatory diseases. 19, 24, 37 The selectins are transmembrane glycoproteins expressed on activated vascular endothelium (P-selectin and E-selectin), activated platelets (P-selectin), and leukocytes (L-selectin), and modulate the early adhesion interactions between endothelium and circulating neutrophils. The role of selectin family molecules in ischemic cerebrovascular disease has been widely investigated in both animal and human studies. 3, 7, 8, 22, 36, 46, 50 These findings underscore the importance of the selectins in the pathophysiological characteristics of tissue injury after cerebral ischemia and reperfusion, and imply that blockade of the selectin family may provide therapeutic benefits. 3, 7, 8, 22, 36, 46, 50 Nevertheless, evidence for a role of the selectins in the pathogenesis of delayed ischemic neurological deficit after aneurysmal SAH is scant. Polin et al. 42 demonstrated elevation of levels of E-selectin, ICAM-1, and VCAM-1 in the CSF of patients after aneurysmal SAH, and E-selectin levels were severely elevated in patients with moderate or severe vasospasm. Contrary to this finding, Nissen and associates 38 reported that there were no significant differences in serum concentrations of ICAM-1, VCAM-1, PECAM, and E-selectin between patients with or without delayed ischemic neurological deficit after aneurysmal SAH. Nevertheless, the P-selectin level was significantly higher and the L-selectin level was significantly lower in patients with delayed ischemic neurological deficit compared with patients without delayed ischemic neurological deficit. 38 Gaetani et al. 18 demonstrated that E-selectin levels in the CSF of patients with ruptured and unruptured aneurysms were below the normal threshold. Our previous study provided the first evidence that pharmacological blockade of E-selectin could partially prevent SAH-induced vasospasm at medium and high doses. 30 These findings also further support the hypothesis that E-selectin may contribute to the pathophysiology of cerebral vasospasm after SAH. Additional experiments are required to fully evaluate the potential use of anti-Eselectin antibody in the treatment of SAH-induced vasospasm. Given the functionally redundant nature of selectin activity, combined blockade of P-selectin and E-selectin might provide more therapeutic benefit than blockade of either molecule separately. Knockout mice with an absence of adhesion molecules may provide further insight into the role of adhesion molecules in the pathogenesis of cerebral vasospasm after SAH. We have found E-selectin levels to be increased in animals subjected to SAH compared with control animals (unpublished data). Endothelin-converting enzyme inhibition did not decrease the production of E-selectin after SAH in the present experiment.
Mounting evidence has implicated ETs in the pathophysiology of cerebral vasospasm. 26, 31 Endothelins, in particular
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Bar graph demonstrating plasma VCAM-1 (VCAM) levels in the four groups of rabbits. There are no significant differences in VCAM-1 levels among the animal groups.
FIG. 3. Bar graph demonstrating plasma E-selectin levels in the four groups of rabbits. Mean levels of E-selectin are increased significantly in the SAH only, SAH plus vehicle, and SAH plus CGS 26303 groups when compared with the mean level in healthy controls. Treatment with CGS 26303 has no effect on the increased levels of E-selectin after SAH. *p Ͻ 0.005, #p Ͻ 0.01, compared with the control group.
ET-1, are among the most potent endogenous vasoconstrictors thus far identified. Clinical studies have shown that elevated levels of ETs are present in the CSF of patients with SAH, 47 suggesting that ET-mediated vasoconstriction contributes to vascular constriction after SAH. The potential involvement of ETs in vasospasm has triggered considerable interest in therapeutic strategies that inhibit the biological effects of ET. Such strategies include the following: 1) blocking the biosynthesis of ETs; 2) reducing extracellular ET levels by specific anti-ET antibodies; and 3) antagonizing ET receptors. 31 One promising approach for blocking the biosynthesis of ETs is to suppress the proteolytic conversion of the precursor peptide (big ET-1) to its vasoactive form (ET-1). Consequently, ECE inhibitors represent logical candidate compounds to block the activation of ETs and to limit spastic constriction. Several lines of evidence indicate that targeting the ET function at the level of proteolytic processing can be of therapeutic value in the treatment of cerebral vasospasm. 5, 10, 27, 28 Fassbender and colleagues 13 demonstrated that activated mononuclear cells in the CSF of patients who had sustained SAH synthesized and released ET-1 in parallel with known acute-phase reactants (interleukins 1␤ and 6 and tumor necrosis factor-␣). These authors also confirmed the leukocyte origin of ET-1 and showed that aging and subsequent hemolysis of the blood clot was sufficient to induce ET-1 production. 13 The fact that ET-1 production occurs by activated leukocytes accompanying an inflammatory response offers the first suggestion of a link between inflammation, ET-1 production or action, and the development of cerebral vasospasm. 11, 13 The use of a number of antiinflammatory treatments has been studied in cerebral vasospasm. A multitude of therapeutic strategies, the majority of which are nonspecific in nature, have been investigated in both laboratory and clinical contexts. Nevertheless, the outcomes of these studies have been equivocal. Such agents as cyclosporine A, FK-506, methylprednisolone, nonsteroidal antiinflammatory agents, and other antiinflammatory drugs have been used with variable success in limiting cerebral vasospasm. 11 Currently, clinical treatment of cerebral vasospasm does not incorporate antiinflammatory therapy. Studies taking into consideration the limitations of previous work are necessary to examine the efficacy of antiinflammatory treatment. Further characterization of the role of inflammation in cerebral vasospasm is needed to fill the considerable gaps in our current knowledge. In addition, delineation of how other specific theories of pathogenesis (and noninflammatory-associated spasmogens) may relate to or contribute to the proposed final common pathway of inflammation is worthy of further studies. Such knowledge may facilitate the development of novel therapies for prevention and/or treatment, which may ultimately translate to clinical practice.
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Conclusions
The effects of ECE inhibitors on the production of ICAM-1, VCAM-1, and E-selectin in the circulation have never been studied. We report the first evidence that an ECE inhibitor did not have effect on the upregulation of E-selectin after SAH. Levels of VCAM-1 displayed no significant changes after SAH, even when treated by an ECE inhibitor. Nevertheless, CGS 26303 treatment significantly lowered the production of ICAM-1 after SAH. Inhibition of ECE may attenuate SAH-induced vasospasm partially by reversal of the upregulation of ICAM-1.
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